nach oben

Erschienen in:

01.12.2014 | Original Research

Efficacy of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to the prostate for intermediate- and high-risk prostate cancer

verfasst von: Krishna Reddy, Tobin Strom, Reed Plimpton, Brian D. Kavanagh, Jane Petersen, Shandra Wilson, Paul Maroni, David Raben

Erschienen in: Journal of Radiation Oncology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Objectives

The objective of this study is to evaluate the efficacy as well as acute and late toxicities of pelvic intensity-modulated radiotherapy (IMRT) with hypofractionated simultaneous integrated boost (SIB) to the prostate for patients with intermediate- and high-risk prostate cancer.

Methods

A retrospective analysis was performed of 66 patients treated definitively with pelvic SIB-IMRT in a prospective fashion; all of whom also received androgen suppression. The IMRT plans were designed to deliver 70 Gy in 28 fractions (2.5 Gy/fraction) to the prostate while simultaneously delivering 50.4 Gy in 28 fractions (1.8 Gy/fraction) to the pelvic lymph nodes.

Results

Forty-four high-risk (GS 8–10, PSA > 20 or ≥ T2c) patients and 22 intermediate-risk (GS7, 10 < PSA < 20 or cT2b) patients received SIB-IMRT. The 3-year and 4-year rates of actuarial freedom from biochemical failure (FFbF) for all patients receiving SIB-IMRT were 89.5 and 83.9 %, respectively. Prostate cancer-specific survival at 3- and 5-year post RT completion was 98.2 and 90.6 %, respectively.

Conclusion

Pelvic IMRT utilizing a simultaneous integrated boost to the prostate appears to be a safe treatment regimen for high- and high-intermediate-risk prostate cancer patients, allowing them to be treated in an accelerated fashion without compromising biochemical control, freedom from distant metastasis, or prostate cancer-specific survival.

Kupelian PA, Willoughby TR, Reddy CA et al (2007) Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer. Cleveland clinic experience. Int J Radiat Oncol Biol Phys 63:1424–1430CrossRef

Kupelian PA, Thakkar VV, Khuntia D et al (2005) Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys 63:1463–1468PubMedCrossRef

Arcangeli G, Saracino B, Gomellini S et al (2010) A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 78(1):11–18PubMedCrossRef

Lukka H, Hayter C, Julian JA, et al. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005: 6132–6138

Yeoh EE, Botten RJ, Butters J et al (2011) Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys 81(5):1271–1278PubMedCrossRef

Pervez N, Small C, MacKenzie M et al (2010) Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 76(1):57–64PubMedCrossRef

Livsey JE, Cowan RA, Wylie JP (2003) Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis. Int J Radiat Oncol Biol Phys 57:1254–1259PubMedCrossRef

Pollack A, Hanlon AL, Horwitz EM et al (2006) Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 64:518–526PubMedCentralPubMedCrossRef

McCammon R, Rusthoven KE, Kavanagh B et al (2009) Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer. Int J Radiat Oncol Biol Phys 75(2):413–420PubMedCrossRef

10.

Di Muzio N, Fiorino C, Cozzarini C et al (2009) Phase I-II study of hypofractionated simultaneous integrated boost with tomotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 74(2):392–398PubMedCrossRef

11.

Arcangeli S, Saracino B, Petrongari MG et al (2007) Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area. Radiother Oncol 84(2):148–155PubMedCrossRef

12.

Lim TS, Cheung PC, Loblaw DA et al (2008) Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results. Int J Radiat Oncol Biol Phys 72(1):85–92PubMedCrossRef

13.

Ippolito E, Cellini N, Digesù C et al (2013) Postoperative intensity-modulated radiotherapy with simultaneous integrated boost in prostate cancer: a dose-escalation trial. Urol Oncol 31(1):87–92PubMedCrossRef

14.

Engels B, Soete G, Tournel K et al (2009) Helical tomotherapy with simultaneous integrated boost for high-risk and lymph node-positive prostate cancer: early report on acute and late toxicity. Technol Cancer Res Treat 8(5):353–59PubMedCrossRef

15.

Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 15; 65 (4): 965–74.

16.

Quon H, Cheung PC, Loblaw DA et al (2012) Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity. Int J Radiat Oncol Biol Phys 82(2):898–905PubMedCrossRef

17.

Guckenberger M, Lawrenz I, Flentje M (2014) Moderately hypofractionated radiotherapy for localized prostate cancer: long-term outcome using IMRT and volumetric IGRT. Strahlenther Onkol 190(1):48–53PubMedCrossRef

18.

Valeriani M, Carnevale A, Osti MF, Minniti G, De Sanctis V, Agolli L, Bracci S, Enrici RM (2013) Hypofractionated intensity-modulated simultaneous integrated boost and image-guided radiotherapy in the treatment of high-risk prostate cancer patients: a preliminary report on acute toxicity. Tumori 99(4):474–9PubMed

19.

Pollack A, Zagars GK, Starkschall G et al (2002) Prostate cancer radiation dose response: results of the MD Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53(5):1097–105PubMedCrossRef

20.

Peeters ST, Heemsbergen WD, Koper PC et al (2006) Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24(13):1990–6PubMedCrossRef

21.

Katz A (2012) Stereotactic body radiotherapy for prostate cancer: ready for prime time? J Radiat Oncol 1(1):17–30CrossRef

Titel: Efficacy of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to the prostate for intermediate- and high-risk prostate cancer
verfasst von: Krishna Reddy
Tobin Strom
Reed Plimpton
Brian D. Kavanagh
Jane Petersen
Shandra Wilson
Paul Maroni
David Raben
Publikationsdatum: 01.12.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Radiation Oncology / Ausgabe 4/2014
Print ISSN: 1948-7894
Elektronische ISSN: 1948-7908
DOI: https://doi.org/10.1007/s13566-014-0163-6

Springer Medizin

Efficacy of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to the prostate for intermediate- and high-risk prostate cancer